Clinical trial data over two years showed patients receiving Merck and Moderna's experimental melanoma vaccine were 42 percent less likely to experience cancer recurrence compared to patients who did not receive the vaccine
Agree
Disagree
Overview
Debates
Related claims
Topics
Best
Space b5a31f
Loading debates…
Opening sign-in…